Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma mass spectrometry

Solovyev, Nikolay; Ala, Aftab; Schilsky, Michael L.; Mills, Craig N.; Willis, Karl D. D.; Harrington, Chris F.

doi:10.1016/j.aca.2019.11.033

Cited by 43 publications

(40 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protein binding testing using “free” (ultrafiltration) platinum assay was undertaken to elucidate the lower observed toxicity, first of all, in the kidney ( Figure 3 ) and liver ( Figure 4 ). Ultrafiltration is a well-accepted approach to evaluate plasma protein binding of the substances in vivo [ 42 ], also widely used in metal toxicology [ 43 , 44 , 45 ]. Interestingly, we showed considerably higher (nearly two-fold) relative protein binding for the HIPEC treatment compared to i.v.…”

Section: Discussionmentioning

confidence: 99%

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

et al. 2020

Self Cite

View full text Add to dashboard Cite

Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an established form of locoregional chemotherapy of peritoneum tumors. However, its efficacy and safety status remain a controversy, partially, due to scarce data on pharmacokinetics and toxicity profile of drugs under HIPEC. In the current study, 24 female Wistar rats were randomly assigned to receive cisplatin as HIPEC (n = 12, 20 mg/kg) or intravenously (i.v., n = 9, 4 mg/kg). The subgroups of three animals were used for the initial, intermediate, and late phases of the pharmacokinetic assessment. The animals were sacrificed on days 1 and 5. Blood, liver, kidney, and ovaries were evaluated for platinum content. Histological and immunohistochemical evaluation was undertaken in the liver and kidney. A trend for higher blood plasma platinum levels was observed for HIPEC compared to i.v. Significantly lower (p < 0.001) relative platinum binding to the proteins was observed in HIPEC animals compared to the i.v. administration. A five-fold higher concentration of cisplatin in HIPEC resulted in a ca. 2.5-fold increase in total blood platinum and ca. two-fold increase in blood ultrafitrable platinum (“free” Pt). Immunohistochemistry revealed higher kidney and liver damage after i.v. administration of cisplatin compared to HIPEC, although a five-fold higher dose of cisplatin was applied in HIPEC. Together with relatively lower absorption to the systemic circulation in HIPEC, higher protein binding is probably the primary reason for lower observed toxicity in HIPEC animals.

show abstract

Section: Discussionmentioning

confidence: 99%

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…• Anion exchange chromatography-triple quadrupole inductively coupled plasma mass spectrometry for simple quantification of ceruloplasmin for a more accurate determination of non-ceruloplasmin copper level (23) cDNA, complementary DNA; CuEXC, exchangeable copper; MR, magnetic resonance; PET, positron emission tomography; WD, Wilson disease.…”

Section: Table 1 Current Advances In Diagnosis and Management Of Wilson Diseasementioning

confidence: 99%

“…Another method of monitoring free copper includes a new method of anion exchange chromatography-triple quadrupole inductively coupled plasma mass spectrometry for simple quantification of ceruloplasmin (23). Previously used immunoassays for ceruloplasmin activity rely on indirect methods and can overestimate the quantity of ceruloplasmin due to presence of the apoprotein.…”

Section: Monitoring Of Treatmentmentioning

confidence: 99%

“…This method of anion exchange chromatography-triple quadrupole inductively coupled plasma mass spectrometry allows for ceruloplasmin quantification with limit of detection of 0.1 mg•L −1 and limit of quantification 0.4 mg•L −1 ). Measurement of non-ceruloplasmin bound copper was also studied using this device and noted that the ultrafiltration method to quantify non-ceruloplasmin copper (NCC) is subjected to overestimation in measurement due to a removal of copper from ceruloplasmin (23). This assay may provide a more accurate understanding of the NCC in patients with WD.…”

Section: Monitoring Of Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in Wilson disease

Moini¹,

To²,

Schilsky³

2021

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

Wilson disease (WD) is rare genetic disorder that presents with varied phenotype that can at times make the diagnosis challenging. Medical treatments are available, but there are still unmet needs for patients. Since life-long therapy is necessary, adherence to medical therapy and best practices for monitoring and individualizing therapy continue to evolve. Studies are ongoing that address some of these issues. In the current review we focused our attention to recent advances in the diagnosis of WD, current medical treatments, future potential therapies and treatment monitoring. We include discussion of new methodology for detection and quantitation of ophthalmologic signs of WD, new brain imaging modalities for early detection of neurologic involvement in patients and potential new diagnostic methodology using blood samples that may be applicable to newborn screening and adult disease diagnosis. In addition, there are new strategies aimed at improving adherence and outcomes with currently available therapies, including once daily chelation dosing and discussion of the efficacy of different zinc salt compounds. With respect to new therapies with different mechanisms of action, we discuss studies on Bis-choline tetrathiomolybdate (TTM) in patients, pre-clinical studies of a novel chelator methanobactin and other animal studies exploring cures for WD with gene therapy using adeno-associated vectors (AAVs) that introduce ATP7B into liver cells. There are also promising advances in the more accurate measurement of non-ceruloplasmin bound copper and exchangeable copper in the circulation which would potentially help with monitoring and individualization of treatment and possibly play a role in future disease diagnosis.

show abstract

“…Lopez-Avila et al presented a novel two-step method for the determination of Cu bound ceruloplasmin using immunoaffinity chromatography followed by SEC-ICP-MS. 28 The immunoaffinity chromatography took 30 minutes (sample-to-sample time) in addition to the 20 minute separation by SEC-ICP-MS for Cu bound ceruloplasmin and extractable copper. Most recently, Solovyev et al presented the ability to determine the speciation of Cu-containing proteins in 10 minutes by AEC-ICP-MS 29 or Cu(I) vs. Cu(II) and CP. 30,31 These methods for the determination of Cu bound ceruloplasmin or extractable copper involve additional sample preparation, two dimensional methods, and/or lengthy analysis times.…”

Section: Introductionmentioning

confidence: 99%